Hair Growth Treatments
Transitions of Indiana, and sister company We Grow Hair Indy, are one of a select group of hair restoration companies nationwide to offer exosome therapy. Exosomes are messengers that deliver 1,000+ growth factor proteins in a single treatment. They are known to stimulate stem cell bioactivity and direct communication while decreasing inflammation and activating your hair follicles. Exosome therapy has been clinically shown to help regenerate and regrow hair in both men and women. Patients have seen hair growth results in as little as three months!
Exosomes vs. Platelate-Rich Plasma (PRP)
Exosome Therapy is a very similar treatment to PRP where it involves the injection of growth factors into your problem areas on the scalp. The Exosome treatment is a little more quick and comfortable because it does not require blood draw like PRP. Because ExoFlo Exosomes are derived from a donor, as opposed to yourself with PRP, we can ensure that the injections you're receiving are of the highest quality. This means that you know you're getting the most amount of concentrated growth factors possible within a single treatment. Exosome Therapy is a great choice for anyone that wants thicker fuller hair, but we highly recommend Exosomes if you're concerned about the quality of your own blood. If you've suffered from significant loss, if you have an autoimmune disease, or if you're getting older and have noticed thinning you may choose Exosome Therpy over PRP.
About Direct Biologics:
- Direct Biologics is a market-leading innovator and science-based biologics manufacturer of regenerative medical products.
- They are committed to quality and patient safety. Their manufacturing facility is an FDA registered CGMP facility that is compliant with the highest standard of processing and manufacturing controls.
- Direct Biologics’ ExoFlo exosomes are minimally-manipulated single-donor-per-lot tissue and contain no animal products, chemicals, or drugs in the processing and isolation of the exosome products.
- Direct Biologics is actively preparing to pursue FDA approval and will be submitting its first of several applications for IND clinical trials in various indications.